LAG-3 and PD-1 combination therapy in tumor immunotherapy.
- Author:
Peng PENG
1
;
Li BAI
2
Author Information
1. Department of Microbiology and Immunology, School of Basic Medical Sciences, Dali University, Dali 671000, China.
2. Department of Microbiology and Immunology, School of Basic Medical Sciences, Dali University, Yunnan Key Laboratory for Biomedical Research and Developme nt of Insects, Dali University, Dali 671000, China. *Corresponding author, E-mail: lbai@dali.edu.cn.
- Publication Type:English Abstract
- MeSH:
Humans;
Neoplasms/immunology*;
Immunotherapy/methods*;
Programmed Cell Death 1 Receptor/metabolism*;
Lymphocyte Activation Gene 3 Protein;
Antigens, CD/metabolism*;
Animals;
Tumor Microenvironment/immunology*;
Immune Checkpoint Inhibitors/therapeutic use*
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(4):355-362
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death 1 (PD-1) and its ligand (PD-L1) serve as crucial targets in cancer immunotherapy, and their inhibitors have significantly improved the prognosis of many patients with malignant tumors. However, the issues of drug resistance and limited overall response rate associated with monotherapy remain prevalent. As a new generation of immune checkpoints, lymphocyte activation gene 3 (LAG-3) synergistically enhances the suppression of T cells alongside PD-1 in various cancers. Combining the blockade of both PD-1 and LAG-3 yields stronger anti-tumor immune effects compared to blocking either target alone, thereby reversing the immunosuppressive state of the tumor microenvironment and reducing the occurrence of resistance. This review covers the structural characteristics of LAG-3 and unveils its specific interactions with PD-1 across multiple cancers, providing a novel reference for overcoming the limitations of single-agent therapy.
